Ryaltris NDC 68462-659

NDC codes

FDA NDC Directory

Product NDC (as listed)68462-659Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68462-0659Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68462-659-27	68462065927	12 CARTON in 1 BOX (68462-659-27) / 1 BOTTLE, SPRAY in 1 CARTON / 240 SPRAY, METERED in 1 BOTTLE, SPRAYMarketed from Jan 13, 2026
68462-659-84	68462065984	12 CARTON in 1 BOX (68462-659-84) / 1 BOTTLE, SPRAY in 1 CARTON / 56 SPRAY, METERED in 1 BOTTLE, SPRAYMarketed from Jan 13, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ryaltris
Generic name (nonproprietary): olopatadine hydrochloride and mometasone furoate
Active ingredients: Olopatadine hydrochloride — 665 ug/1Mometasone furoate monohydrate — 25 ug/1
Dosage form: Spray, Metered
Route: Nasal
Labeler: Glenmark Pharmaceuticals Inc., USA
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 211746
Marketing start: Jan 13, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)Corticosteroid Hormone Receptor Agonists (Mechanism)Decreased Histamine Release (Physiologic effect)Histamine H1 Receptor Antagonists (Mechanism)
Identifiers: Product ID 68462-659_ecbea621-93b0-40ce-adce-1d304c4fdb15SPL ID ecbea621-93b0-40ce-adce-1d304c4fdb15SPL set ID 406be932-f00e-4c66-9dd1-c142090fe822RxCUI 2591806, 2591812UNII 2XG66W44KF, MTW0WEG809UPC 0368462659274
Pharmacologic class: Corticosteroid; Histamine-1 Receptor Antagonist; Histamine-1 Receptor Inhibitor; Mast Cell Stabilizer

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Nasal products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468462065927 followed by a unit qualifier and the quantity

Package 68462-0659-27. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 21, 2026.

Indications (excerpt from the label)

RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients of age 6 years and older. RYALTRIS is a combination of olopatadine, a histamine-1 (H1)-receptor inhibitor, and mometasone furoate, a corticosteroid, indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 211746

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 211746
Product	Strength	Form · route	Labeler	Product NDC
Ryaltrisolopatadine hydrochloride and mometasone furoate	Olopatadine hydrochloride 665 ug/1; Mometasone furoate monohydrate 25 ug/1	Spray, MeteredNasal	HIKMA SPECIALTY USA INC.	59467-700